Capricor’s cell therapy shows three year benefit in DMD patients

Capricor Therapeutics has announced its deramiocel cell therapy continues to be safe and effective after three years for Duchenne muscular dystrophy (DMD).

The Phase II (NCT03406780) three-year open-label extension (OLE) study showed that deramiocel led to a 47% slowing of disease in skeletal muscle in patients with DMD.